Subscribe to our Email Alerts
Neuren Pharmaceuticals
  • Home
  • About Us
    • Company Overview
    • Company Values
    • Board of Directors
    • Executive Management
    • Corporate Directory
  • Products
    • DAYBUE™ (trofinetide)
  • Pipeline
    • Pipeline
    • Trofinetide
      • Rett Syndrome
    • NNZ-2591
      • Phelan-McDermid Syndrome
      • Angelman Syndrome
      • Pitt Hopkins Syndrome
      • Hypoxic-ischemic encephalopathy
      • Prader-Willi Syndrome
  • Science
    • Science Behind Neuren's Products
    • Trofinetide Published Studies & Presentations
      • Rett Syndrome
    • NNZ-2591Published Studies & Presentations
      • Phelan-McDermid Syndrome
      • Pitt Hopkins Syndrome
      • Angelman Syndrome
  • Investors
    • Investor Dashboard
    • Share Price Information
    • ASX Announcements
    • Annual and Interim Reports
    • Investor Presentations
    • Corporate Governance
    • Analyst Coverage
    • Shareholder Services
  • News & Media
    • Media
  • Contact
    • Contact Us
    • Email Alerts

Investors

 

Home > Investors > Corporate Governance
  • Investor Dashboard
  • Share Price Information
  • ASX Announcements
  • Annual and Interim Reports
  • Investor Presentations
  • Corporate Governance
  • Analyst Coverage
  • Shareholder Services

Corporate Governance

 Code of Conduct (0.10MB)

Securities Trading Policy (0.08MB)

Audit Committee Charter (0.09MB)

Remuneration Committee Charter (0.08MB)

Risk Management Policy (0.06MB)

Continuous Disclosure Policy (0.11MB)

Whistleblower Policy (0.16MB)

Anti-bribery and Corruption Policy (0.12MB)

Quick Links

Contact Us

Neuren Pharmaceuticals Limited
Suite 201, 697 Burke Road
Camberwell, VIC 3124
Australia

Phone: +61 (3) 9092 0480
Email: enquiries@neurenpharma.com

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Neuren Pharmaceuticals
Site Map Privacy Search
Site by